Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pharmacokinetics of Salmeterol Via HandiHaler® in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Salmeterol capsule - low
Drug: Salmeterol via Serevent® Diskus®
Drug: Salmeterol capsule - high

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02254187

Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck

Phase 1

Completed

Conditions: Head and Neck Neoplasms

Interventions: Drug: bivatuzumab mertansine

First Posted Date: 2014-10-01

Last Posted Date: 2023-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 31

Registration Number: NCT02254018

Tolerability and Pharmacokinetics/-Dynamics of Single Rising Doses BIBT 986 BS in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBT 986 BS - single rising dose
Drug: Placebo

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 47

Registration Number: NCT02254057

Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus

Phase 1

Terminated

Conditions: Carcinoma, Squamous Cell

Interventions: Drug: bivatuzumab mertansine

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 7

Registration Number: NCT02254044

Pharmacokinetic of Tadalafil Co-administered With Tipranavir/Ritonavir to Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tadalafil
Drug: Tipranavir
Drug: Ritonavir

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 17

Registration Number: NCT02253862

Tolerability and Pharmacokinetics/-Dynamics of BIBT 986 BS in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBT 986 BS - high
Drug: BIBT 986 BS - low
Drug: Placebo

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02254083

Safety, Pharmacokinetics and Pharmacodynamics of BIRT 1696 BS in Healthy Human Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIRT 1696 BS
Drug: Placebo
Other: Grapefruit juice (GFJ)
Other: High fat meal (HFM)

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 46

Registration Number: NCT02254096

Pharmacokinetics of Salmeterol (Serevent®) After Inhalation With Metered Dose Inhaler (MDI) and Diskus® in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Salmeterol MDI high
Drug: Salmeterol Diskus low
Drug: Salmeterol Diskus high
Drug: Salmeterol MDI low

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 26

Registration Number: NCT02254226

Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BEA 2180 BR in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BEA 2180 BR - rising dose

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02254135

Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of BILR 355 BS Plus Low Dose Ritonavir in HIV-uninfected Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BILR 355 BS, solution
Drug: BILR 355 BS, tablet
Drug: Ritonavir

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 100

Registration Number: NCT02253914

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy